T. Rowe Price Investment Management, Inc. Biogen Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,256,286 shares of BIIB stock, worth $634 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
4,256,286
Previous 5,678,859
25.05%
Holding current value
$634 Million
Previous $1.32 Billion
37.33%
% of portfolio
0.5%
Previous 0.83%
Shares
6 transactions
Others Institutions Holding BIIB
# of Institutions
1,037Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.49 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.43 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.17 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.09 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA5.13MShares$765 Million0.18% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.5B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...